

Amendments to the Specification:

Paragraph 1 at page 1, line 5 after the heading "CROSS-REFERENCE TO RELATED APPLICATIONS" has been replaced with:

This application is a divisional of Application Serial No. 10/352,745 filed January 28, 2003, now U.S. Patent 6,696,431 which in turn is a divisional of Application Serial No. 10/001,711 filed October 31, 2001, which in turn is a divisional of Application Serial No. 09/540,686 filed March 31, 2001, now U.S. Patent No. 6,392,071, which in turn is a continuation of Application Serial No. 09/370,966 filed August 10, 1999, now abandoned, which in turn is a continuation of Application Serial No. 09/151,113 filed September 10, 1998, now U.S. Patent 5,936,133, which in turn is a divisional of Application Serial No. 08/819,693 filed March 17, 1997, now U.S. Patent No. 5,843,928.

Please replace paragraph 22 at page 11 with:

The preparation of 1 α -hydroxy-2-alkylidene-19-nor-vitamin D compounds, particularly 1 α -hydroxy-2-methylene-19-nor-vitamin D compounds, having the basic structure I can be accomplished by a common general method, i.e. the condensation of a bicycle Windaus-Grudmann type ketone II with the allylic phosphine oxide III to the corresponding 2-methylene-19-nor-vitamin D analogs IV followed by deprotection at C-1 and C-3 in the latter compounds:


Please replace Table 4, at page 28 with:

Table 4. Support of Intestinal Calcium Transport and Bone Calcium Mobilization by 2-Substituted Analogs of 20(S)-1 α ,25-Dihydroxy-26,27-dihomo-19-norvitamin D₃ in Vitamin D-Deficient Rats on a Low-Calcium Diet^a

Compound	Compd. no.	Amount (pmol)	Ca Transport S/M (mean \pm SEM)	Serum Ca (mean \pm SEM)
none (control)		0	2.7 \pm 0.3 ^b	4.7 \pm 0.2 ^b
1 α ,25-(OH) ₂ D ₃		260	7.2 \pm 0.6 ^c	5.6 \pm 0.2 ^c
2-methylene-26,27-dihomo-	35	15	4.0 \pm 0.4 ^{d1}	5.3 \pm 0.1 ^{d1}
19-nor-20(S)-1 α ,25-(OH) ₂ D ₃		32	8.2 \pm 0.6 ^{d2}	7.3 \pm 0.4 ^{d2}

Please replace Scheme III at page 41 and Scheme IV at page 42 as follows:

SCHEME III



SCHEME IV

